American Society of Hematology (ASH)
Refine Search
Biotechnology
News early in last week was dominated by presentations at the American Society of Hematology (ASH) meeting. Among these was AstraZeneca, which released new data on the benefits of adding venetoclax to its Calquence in chronic leukemia. Also showing at ASH was Sino-American biotech BeiGene, which focused its presentations on Brukinsa in leukemia and lymphoma. On the regulatory front, shares of Dutch gene therapy uniQure leapt on news that it had agreed a path forward for its Huntington’s candidate AMT-130. US biotech Q32 Bio released Ph IIA trial results for its bempikibart for alopecia areata that were described as “messy,” sending the firm’s shares plunging 75%. Keros Therapeutics was another big faller after the news that it was halting parts of its Phase II program with cibotercept in pulmonary hypertension. 15 December 2024
Biotechnology
Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. 10 December 2024
Biotechnology
BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2024
Biotechnology
US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 10 December 2024
Biotechnology
Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma. 10 December 2024
Biotechnology
Gilead Sciences has revealed promising five-year data from its Phase II ZUMA-5 trial of Yescarta (axicabtagene ciloleucel), at the American Society of Hematology meeting. 10 December 2024
Biotechnology
French biotechnology company MaaT Pharma remains at the forefront of microbiome-based therapies, with new data on MaaT013 showing strong potential in acute graft-versus-host disease (aGvHD). 10 December 2024
Biotechnology
New data from Johnson & Johnson's Phase III CARTITUDE-4 study highlight the performance of Carvykti (ciltacabtagene autoleucel) in multiple myeloma. 10 December 2024
Biotechnology
Johnson & Johnson has announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM), regardless of transplant status. 9 December 2024
Biotechnology
Pierre Fabre has presented updated Phase III results for its investigational therapy tabelecleucel at the American Society of Hematology (ASH) Annual Meeting. 9 December 2024
Biotechnology
Dizal has announced the latest data from a pooled safety and efficacy analysis of DZD8586, a non-covalent blood-brain barrier (BBB) penetrant LYN/BTK dual inhibitor, in B-cell non-Hodgkin lymphoma (B-NHL). 9 December 2024
Biotechnology
AbbVie has announced updated results from the Phase Ib/II EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide and rituximab (R2) in relapsed or refractory (R/R) follicular lymphoma (FL). 9 December 2024
Biotechnology
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to venetoclax led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). 9 December 2024
Pharmaceutical
Chinese biotech Abbisko Therapeutics has shared Phase II trial results for its oral CSF-1R inhibitor pimicotinib at the 66th ASH annual conference in San Diego. 9 December 2024
Biotechnology
Johnson & Johnson has unveiled positive early data for its multiple myeloma treatment Tecvayli (teclistamab) from two clinical studies focused on people with newly diagnosed multiple myeloma. 9 December 2024
Biotechnology
Positive new five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy (polatuzumab vedotin) in combination with MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL) were released on Sunday by Swiss pharma giant Roche. 9 December 2024
Pharmaceutical
Sanofi has unveiled promising Phase III results for rilzabrutinib, its oral Bruton’s tyrosine kinase (BTK) inhibitor, at this year’s American Society of Hematology (ASH) meeting. 9 December 2024
Biotechnology
US biotech Regeneron Pharmaceuticals on Sunday announced positive updated Phase III data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran (poze-cemdi) combination treatment against ravulizumab, a standard-of-care complement factor 5 (C5) inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). 9 December 2024
Pharmaceutical
The world’s hematologists are packing their bags in preparation for a visit to San Diego, California, for the American Society of Hematology (ASH) Annual Meeting and Exposition. Which companies’ data will they be looking out for? And which might take them by surprise? Our guide below offers a preview of some of the major presentations coming up. 1 December 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Biotechnology
News early in last week was dominated by presentations at the American Society of Hematology (ASH) meeting. Among these was AstraZeneca, which released new data on the benefits of adding venetoclax to its Calquence in chronic leukemia. Also showing at ASH was Sino-American biotech BeiGene, which focused its presentations on Brukinsa in leukemia and lymphoma. On the regulatory front, shares of Dutch gene therapy uniQure leapt on news that it had agreed a path forward for its Huntington’s candidate AMT-130. US biotech Q32 Bio released Ph IIA trial results for its bempikibart for alopecia areata that were described as “messy,” sending the firm’s shares plunging 75%. Keros Therapeutics was another big faller after the news that it was halting parts of its Phase II program with cibotercept in pulmonary hypertension. 15 December 2024
Biotechnology
Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. 10 December 2024
Biotechnology
BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2024
Biotechnology
US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 10 December 2024
Biotechnology
Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma. 10 December 2024
Biotechnology
Gilead Sciences has revealed promising five-year data from its Phase II ZUMA-5 trial of Yescarta (axicabtagene ciloleucel), at the American Society of Hematology meeting. 10 December 2024
Biotechnology
French biotechnology company MaaT Pharma remains at the forefront of microbiome-based therapies, with new data on MaaT013 showing strong potential in acute graft-versus-host disease (aGvHD). 10 December 2024
Biotechnology
New data from Johnson & Johnson's Phase III CARTITUDE-4 study highlight the performance of Carvykti (ciltacabtagene autoleucel) in multiple myeloma. 10 December 2024
Biotechnology
Johnson & Johnson has announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM), regardless of transplant status. 9 December 2024
Biotechnology
Pierre Fabre has presented updated Phase III results for its investigational therapy tabelecleucel at the American Society of Hematology (ASH) Annual Meeting. 9 December 2024
Biotechnology
Dizal has announced the latest data from a pooled safety and efficacy analysis of DZD8586, a non-covalent blood-brain barrier (BBB) penetrant LYN/BTK dual inhibitor, in B-cell non-Hodgkin lymphoma (B-NHL). 9 December 2024
Biotechnology
AbbVie has announced updated results from the Phase Ib/II EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide and rituximab (R2) in relapsed or refractory (R/R) follicular lymphoma (FL). 9 December 2024
Biotechnology
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to venetoclax led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). 9 December 2024
Pharmaceutical
Chinese biotech Abbisko Therapeutics has shared Phase II trial results for its oral CSF-1R inhibitor pimicotinib at the 66th ASH annual conference in San Diego. 9 December 2024
Biotechnology
Johnson & Johnson has unveiled positive early data for its multiple myeloma treatment Tecvayli (teclistamab) from two clinical studies focused on people with newly diagnosed multiple myeloma. 9 December 2024
Biotechnology
Positive new five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy (polatuzumab vedotin) in combination with MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL) were released on Sunday by Swiss pharma giant Roche. 9 December 2024
Pharmaceutical
Sanofi has unveiled promising Phase III results for rilzabrutinib, its oral Bruton’s tyrosine kinase (BTK) inhibitor, at this year’s American Society of Hematology (ASH) meeting. 9 December 2024
Biotechnology
US biotech Regeneron Pharmaceuticals on Sunday announced positive updated Phase III data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran (poze-cemdi) combination treatment against ravulizumab, a standard-of-care complement factor 5 (C5) inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). 9 December 2024
Pharmaceutical
The world’s hematologists are packing their bags in preparation for a visit to San Diego, California, for the American Society of Hematology (ASH) Annual Meeting and Exposition. Which companies’ data will they be looking out for? And which might take them by surprise? Our guide below offers a preview of some of the major presentations coming up. 1 December 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze